

## **FOR IMMEDIATE RELEASE**

CONTACT INFORMATION
DSG Inc.
+1 (484) 913-0210



### **ARIOSA DIAGNOSTICS SELECTS DSG AS EDC PROVIDER**

*— DSG's electronic data capture used by Ariosa Diagnostics in study on safe, new methods for prenatal testing —*

**MALVERN, Pa., April, 2012** — Ariosa Diagnostics, a molecular diagnostics company focused on prenatal testing, has chosen to use DSG's eCaseLink EDC (electronic data capture) system for the NEXT (Non-Invasive Chromosomal Examination of Trisomy) study.

DSG's eCaseLink system captures study data electronically at the point of research, making data collection highly efficient. At any time throughout the study, clean, accurate data is available for review. DSG's eCaseLink allows Ariosa not only to collect and manage their data in real time, but also gives them the option of adding needed functionality as the study progresses.

Ariosa's NEXT study focuses on the non-invasive detection of fetal trisomy-21 during the first trimester of pregnancy. Current methods of prenatal testing have drawbacks; invasive procedures can put both mother and fetus at risk, while conventional screening methods lack accuracy and can be difficult to implement. The NEXT study will compare the effectiveness of Ariosa's prenatal test against current standard first trimester screening for fetal Trisomy 21 detection.

"Ariosa Diagnostics would like to publicly thank DSG for the great customer service that you have provided in support of this project. It isn't over yet but I wanted to put this out there now. Thanks for everything you have done so far. You have gone over and above to help get as much as we can out of the system with weekend and evening support and you always have a positive can-do attitude. Thanks for that!"

Said the Director of Clinical Development at Ariosa Diagnostics

"DSG is pleased to partner with Ariosa Diagnostics on their study. With the use of DSG's unique eCaseLink EDC system, we are confident in the successful outcome of the trial," says Tony Varano, CEO of DSG.

**About Ariosa Diagnostics**

Ariosa Diagnostics, Inc., is a molecular diagnostics company committed to providing safe, highly accurate, and affordable prenatal tests for maternal and fetal health. Led by an experienced team, Ariosa is using its proprietary technology to perform a directed analysis of cell-free DNA in blood. Ariosa's simple blood test equips pregnant women and their healthcare providers with reliable information to make decisions regarding their health, without creating unnecessary stress or anxiety. The company began operations in 2010 and is headquartered in San Jose, California.

For more information, visit [www.ariosadx.com](http://www.ariosadx.com).

**About DSG**

DSG Inc. supports clinical trial data collection and management with innovative technology solutions, including Electronic Data Capture with specialized Clinical Data Management services, IWRS, Clinical Trial Management Systems and digital on-demand Case Report Form publishing management software. DSG's products allow user-friendly, accurate and efficient data capture at any investigator site regardless of the technological infrastructure. DSG has successfully supported over 1,500 clinical trials for more than 400 companies at over 25,000 sites in over 90 countries. Founded in 1992, DSG is a global company headquartered in Malvern, Pa., with additional offices in the U.S., Japan and India. For more information, please visit [www.dsg-us.com](http://www.dsg-us.com).

All products and services mentioned in this announcement are the property of their respective owners.